Rufinamide

According to the letter from House Republicans, the FDA ended its surprise foreign inspection program in a bid to engender deeper collaboration with India. Once again, U.S. lawmakers are pressing the Food and Drug Administration for clarity around the agency’s tracking of scarce medicines and foreign inspection priorities. After contacting the FDA back in July, Republicans on the House Committee on Energy and Commerce are digging into a Bloomberg report stating that the agency has put the kibosh on its unannounced foreign inspection program.  Drug shortages have become increasingly common and drawn-out affairs in the U.S. in recent years, with medications such as amoxicillin, penicillin, Adderall and certain chemotherapies being some of the most recent and high-profile products to run scarce. Throughout 2023, the issue has garnered concern from U.S. officials and lawmakers on both sides of the aisle. Those shortages can be blamed, at least in part, on the FDA’s wind-down of inspectional activities overseas, a trio of Energy and Commerce Committee Republicans alleged in a letter this week. “The U.S. cannot afford additional disruptions to the drug supply chain that reduce the availability of essential medications and force doctors and patients to make difficult treatment decisions,” the Republican lawmakers wrote to FDA Commissioner Robert Califf, M.D. In their letter, the lawmakers cited a 2022 study that showed FDA foreign inspections were down 79% last year compared to 2019, while the number of citations from the regulator “’rose dramatically.’” The letter also singled out a slew of recalls by Indian drugmakers in recent months, as well as a number of plant closures in the U.S., both of which could further plunge the pharmaceutical supply chain into further uncertainty. Back in August, for instance, Alembic recalled more than 80,000 bottles of the bacterial eye infection treatment tobramycin, while the U.S. unit of India’s Aurobindo pulled 96 bottles of rufinamide tablets for treating seizure disorders. In both cases, the recalls were initiated due to the products being distributed throughout the U.S. without being approved. Elsewhere, Pfizer spent much of the second half of the year working with the FDA to right the ship at its Rocky Mount, North Carolina facility, which was damaged by a tornado this past summer. The House Committee has been investigating FDA’s foreign drug inspection program for some time. The committee says it sent a letter requesting information and documents in July, but as of mid-December, hasn’t received any response. Now, three committee members—Cathy Rodgers (R-WA), H. Morgan Griffith (R-VA) and Brett Guthrie (R-KY)—are seeking answers to nearly two-dozen questions around the FDA’s inspectional oversight, specifically concerning the agency’s operations in both China and India. They’re giving the FDA three weeks to respond. This isn’t the first time U.S. lawmakers have targeted the nation’s regulatory authority. Earlier this year, Republican leaders from the Energy and Commerce Committee separately pressed FDA Commissioner Califf to respond to questions on the FDA’s tracking of scarce medicines, its inspection priorities and what the agency has done to parse and prevent shortages for than half a dozen drugs. And in July, the ranking member of the Committee, Frank Pallone Jr. (D-NJ), urged House Republicans to take up legislation that would include FDA-related oversight in the reauthorization of the Pandemic and All-Hazards Prevention Act (PAHPA). Just last month, meanwhile, the chairman of the House Committee on Oversight and Accountability, James Comer (R-KY), and Lisa McClain (R-MI), chairwoman of the Subcommittee on Health Care and Financial Services, requested documents and a staff-level briefing from the FDA to parse through the agency’s shortage mitigation strategies.

各位尊敬的作者、专家：《中国医药工业杂志》2023年第8期杂志已经出版。内容精彩，请大家多多关注！谢谢！本期导读：盐酸奥扎莫德的合成研究进展王军政 王冬梅 杨天明*专论与综述     盐酸奥扎莫德的合成研究进展片剂崩解影响因素及崩解机制的研究进展提高可溶微针载药量方法的研究进展药物包衣操作的在线检测技术及过程模拟研究进展研究论文枸橼酸托法替布的精制工艺和杂质研究奈玛特韦手性中间体的合成工艺改进罗拉匹坦关键中间体的合成工艺改进1α-羟基胆固醇的合成工艺改进瑞舒伐他汀钙有关物质的合成多黏菌素B生产菌多黏芽孢杆菌的选育和发酵过程优化阿奇霉素干混悬剂的制备及体内外评价冰片修饰卡马西平PLGA纳米粒的制备及其在小鼠体内的组织分布卡巴他赛纳米脂质体冻干工艺的考察陈皮配方颗粒提取工艺的优化娑罗子肠溶微丸胶囊的制备及质量评价卢非酰胺片的处方优化及初步评价药学管理与信息欧盟和美国的平行科学建议制度对我国沟通交流制度的启示化学仿制药微球注射剂药学研究的一般考虑我国《鼓励研发申报儿童药品清单》的政策实施效果及优化仿制药替代政策研究的可视化分析年度发布2023年《全球药研新动态》《中国医院市场用药格局》（2023版）2023年《数图药讯》权威发布2021年度中国医药工业百强榜单解读中国仿制药发展报告（2022版）《2023年专利到期药品概述》医药行业专项报告中国医药中间体和原料药行业调研报告中国非甾体抗炎类原料药市场调研报告中国祛痰类原料药市场调研报告中国钙拮抗剂类原料药市场调研报告中国血管紧张素Ⅱ受体拮抗剂类原料药市场调研报告中国口服血糖调节类原料药市场调研报告中国中枢兴奋类原料药市场调研报告中国抗痛风类原料药市场调研报告中国脑血管病类原料药市场调研报告END如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001